In addition, combined application with STING agonists can not only reduce the dosage and side effects of radiotherapy, chemotherapy, tumor vaccines, immune checkpoint inhibitors, chimeric antigen receptor T-cell (CAR-T) immunotherapy or other types of treatments, but also can synergistically enhance anti-tumor effects through different mechanisms. This evidence concerns the gene STING1 and neoplasm.